Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Sol-Gel Technologies Ltd. SLGL

11 fiscal years on record · USD · FY2025 reported · SEC filings only
$19.4M
▲ 68.0% YoY
$-6.1M
$275,000

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 19.4M
Revenue, FY2025 · full 11-year series below
Revenue $M Net income $M
FY2025 · Revenue 19.4 · Net income -6.1
15M30M-15M-30M
20152018202120242025
Compound annual growth
+70.9%
+17.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +17.2% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−32 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -38.9% · Net -31.6%
-10000%-20000%
201520202025
ROE
FY2025 · ROE -23.7%
-20%-40%-60%
201520202025
Three returns, three denominators.

Each USD of equity lost 24 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 0.3
-10M-20M
201520202025

Total assetsUSD 29.9M
EquityUSD 22.8M
CashUSD 11.0M
Current ratio4.37×

Equity funds 76% of total assets.

The 11-year record

11 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
SLGL, 11-year financial record
Metric 20252024202320222021202020192018201720162015
Revenue $B0.00.00.00.00.00.00.00.00.0◌◌
Operating income $B−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.0◌0.00.00.0◌◌◌◌
Net income $B−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−2.19−3.79−10.01−0.650.14−1.30−1.261.805.023.301.53
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————
ROE %−23.7−31.4−67.4−30.56.1−56.7−42.3————
Shares out B0.000.030.030.020.020.020.020.020.010.01◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 42 reconciliationsAUDITED

Reconciled in 11 of the 11 fiscal years we could check. 18 checks were skipped: the balance sheet is not tagged before 2016. Eight checks were skipped: EPS is not tagged before 2015.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code L3
Fiscal year endsDecember 31
Data on record since2015

Share this section

Download image